EGFR and non-small cell lung carcinoma: A similar epidemiologic analysis was performed by Rachiglio and Colleagues on a cohort of 133 advanced and metastatic NSCLC patients recruited from seven Southern and Central Italy hospitals and treated with first-line therapy EGFR tyrosine kinase inhibitors (TKIs).